- Home
- MYO vs ANTX Comparison
MYO vs ANTX Comparison
Compare MYO & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYO | ANTX |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.9M | 31.2M |
| IPO Year | 2017 | 2022 |
Fundamental Metrics
Financial Performance| Metric | MYO | ANTX |
|---|---|---|
| Price | $0.89 | $1.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $7.67 | $2.00 |
| AVG Volume (30 Days) | ★ 557.1K | 134.3K |
| Earning Date | 03-09-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,643,203.00 | N/A |
| Revenue This Year | $24.07 | N/A |
| Revenue Next Year | $17.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 65.00 | N/A |
| 52 Week Low | $0.71 | $1.00 |
| 52 Week High | $6.44 | $1.55 |
Technical Indicators
Market Signals| Indicator | MYO | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.61 | 51.99 |
| Support Level | $0.92 | $1.15 |
| Resistance Level | $1.02 | $1.28 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 17.58 | 45.47 |
Price Performance
Historical ComparisonAbout MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.